focus -WSS

focus

author：knowledge 2025-10-01 21:08:58 - browse：36283

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： STAT reporters are Pulitzer Prize finalists for investigative reporting

WSS

The haunting brain science of long Covid

'Investigate these claims': UFO transparency at center of House hearing

As H5N1 spreads in cows, experts warn against drinking raw milk

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

knowledge

focus

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ripples from Flovent's discontinuation is killing children with asthma

Supreme Court strikes down use of affirmative action

In the gardens at Boston Children's Hospital, families find sanctuary

Dobbs anniversary: the lost opportunity of abortion as health care

New Alzheimer's drugs heat up race for early detection blood tests

Affirmative action in medical school literally saved lives

Rise in cancer among younger people worries and puzzles doctors

Continuity nursing helped my family in our darkest PICU moments

CVS is willing to dump 10% of its Medicare Advantage members

focus

STAT series 'Denied by AI' wins major journalism prizes

UHS says company favors patients whose insurance pays more

A new crop of companies is reshaping the health data economy

Boston hospital trains restaurant workers on naloxone for overdoses

In the gardens at Boston Children's Hospital, families find sanctuary

New lawsuit accuses health insurer Cigna of denying claims in bulk

Wikipedia

focus

focus

hotspot